1
|
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz HJ, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, El Khoueiry A, Azad NS. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Int J Cancer 2024; 154:1794-1801. [PMID: 38312102 DOI: 10.1002/ijc.34845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 08/22/2023] [Accepted: 09/07/2023] [Indexed: 02/06/2024]
Abstract
DNA methyltransferase inhibitors (DNMTi) have demonstrated benefit in reversing resistance to systemic therapies for several cancer types. In a phase II trial of guadecitabine and irinotecan compared to regorafenib or TAS-102 in pts with advanced mCRC refractory to irinotecan. Patients with mCRC refractory to irinotecan were randomized 2:1 to guadecitabine and irinotecan (Arm A) vs standard of care regorafenib or TAS-102 (Arm B) on a 28-day cycle. Between January 15, 2016 and October 24, 2018, 104 pts were randomized at four international sites, with 96 pts undergoing treatment, 62 in Arm A and 34 in Arm B. Median overall survival was 7.15 months for Arm A and 7.66 months for Arm B (HR 0.93, 95% CI: 0.58-1.47, P = .75). The Kaplan-Meier rates of progression free survival at 4 months were 32% in Arm A and 26% in Arm B. Common ≥Grade 3 treatment related adverse events in Arm A were neutropenia (42%), anemia (18%), diarrhea (11%), compared to Arm B pts with neutropenia (12%), anemia (12%). Guadecitabine and irinotecan had similar OS compared to standard of care TAS-102 or regorafenib, with evidence of target modulation. Clinical trial information: NCT01896856.
Collapse
Affiliation(s)
- Valerie Lee
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Rose Parkinson
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Marianna Zahurak
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Leslie Cope
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Andrea Cercek
- Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Henk Verheul
- Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Elske Gootjes
- Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Heinz Josef Lenz
- School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Syma Iqbal
- School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Peter Jones
- Van Andel Institute, Grand Rapids, Michigan, USA
| | - Stephen Baylin
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Vandna Rami
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Nita Ahuja
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Anthony El Khoueiry
- School of Medicine, University of Southern California, Los Angeles, California, USA
| | - Nilofer S Azad
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| |
Collapse
|
2
|
Baretti M, Karunasena E, Zahurak M, Walker R, Zhao Y, Pisanic TR, Wang TH, Greten TF, Duffy AG, Gootjes E, Meijer G, Verheul HMW, Ahuja N, Herman JG, Azad NS. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clin Transl Sci 2021; 14:954-963. [PMID: 33811727 PMCID: PMC8212722 DOI: 10.1111/cts.12960] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 11/17/2020] [Accepted: 11/22/2020] [Indexed: 12/13/2022] Open
Abstract
Abstract We previously reported CHFR methylation in a subset of colorectal cancer (CRC; ∼30%) with high concordance with microsatellite instability (MSI). We also showed that CHFR methylation predicted for sensitivity to docetaxel, whereas the MSI‐high phenotypes were sensitive to gemcitabine. We hypothesized that this subset of patients with CRC would be selectively sensitive to gemcitabine and docetaxel. We enrolled a Phase 2 trial of gemcitabine and docetaxel in patients with MSI‐high and/or CHFR methylated CRC. The primary objective was Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response rate. Enrolled patients were treated with gemcitabine 800 mg/m2 on days 1 and 8 and docetaxel 70 mg/m2 on day 8 of each 21‐day cycle. A total of 6 patients with CHFR‐methylated, MSI‐high CRC were enrolled from September 2012 to August 2016. The study was closed in September of 2017 due to poor accrual prior to reaching the first interim assessment of response rate, which would have occurred at 10 patients. No RECIST criteria tumor responses were observed, with 3 patients (50%) having stable disease as best response, 1 lasting more than 9 months. Median progression‐free survival (PFS) was 1.79 months (95% confidence interval [CI] = 1.28, not available [NA]) and median overall survival (OS) was 15.67 months (95% CI = 4.24, NA). Common grade 3 toxicities were lymphopenia (67%), leukopenia (33%), and anemia (33%). Although negative, this study establishes a proof‐of‐concept for the implementation of epigenetic biomarkers (CHFR methylation/MSI) as inclusion criteria in a prospective clinical trial to optimize combinatorial strategies in the era of personalized medicine. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
CHFR silencing via DNA methylation has been suggested to be predictive of taxane sensitivity in diverse tumors. The frequent association of CHFR methylation with microsatellite instability (MSI) suggested a possible combination therapy with gemcitabine, because the MSI phenotype may result in sensitivity to nucleoside analogues.
WHAT QUESTION DID THIS STUDY ADDRESS?
We hypothesized that metastatic colorectal cancer (mCRC), which have CHFR methylation and MSI phenotype were sensitive to gemcitabine and docetaxel, and have designed this Phase 2 trial in biomarker‐selected mCRC to test this prediction.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
The study enrolled a molecularly defined subgroup of patients with colorectal cancer (CRC) and showed that the combination is safe in this population. Nevertheless, due to poor enrollment and early termination, no conclusions on the primary and secondary end points could be made.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
This study supports the feasibility of implementing DNA methylation markers in a prospective clinical trial and further efforts toward their application as predictive biomarkers for therapeutic agents in defined subsets of patients are warranted.
Collapse
Affiliation(s)
- Marina Baretti
- Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
| | - Enusha Karunasena
- Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
| | - Marianna Zahurak
- Department of Oncology, Biostatistics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Rosalind Walker
- Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
| | - Yang Zhao
- Johns Hopkins Institute for NanoBioTechnology, Baltimore, Maryland, USA
| | - Thomas R Pisanic
- Johns Hopkins Institute for NanoBioTechnology, Baltimore, Maryland, USA
| | - Tza-Huei Wang
- Johns Hopkins Institute for NanoBioTechnology, Baltimore, Maryland, USA
| | - Tim F Greten
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Austin G Duffy
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Elske Gootjes
- Amsterdam University Medical Center, location VUMC, Amsterdam and Radboud UMC, Nijmegen, The Netherlands
| | - Gerrit Meijer
- Amsterdam University Medical Center, location VUMC, Amsterdam and Radboud UMC, Nijmegen, The Netherlands
| | - Henk M W Verheul
- Amsterdam University Medical Center, location VUMC, Amsterdam and Radboud UMC, Nijmegen, The Netherlands
| | - Nita Ahuja
- Oncology and Pathology, Smilow Cancer Hospital, Yale University School of Medicine, New Haven, Connecticut, USA
| | - James G Herman
- Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Nilofer S Azad
- Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
| |
Collapse
|
3
|
Lee V, Wang J, Zahurak M, Gootjes E, Verheul HM, Parkinson R, Kerner Z, Sharma A, Rosner G, De Jesus-Acosta A, Laheru D, Le DT, Oganesian A, Lilly E, Brown T, Jones P, Baylin S, Ahuja N, Azad N. A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Clin Cancer Res 2018; 24:6160-6167. [PMID: 30097434 DOI: 10.1158/1078-0432.ccr-18-0421] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 04/29/2018] [Accepted: 08/07/2018] [Indexed: 11/16/2022]
Abstract
PURPOSE Chemotherapeutic resistance eventually develops in all patients with metastatic colorectal cancer (mCRC). Gene silencing through promoter demethylation is one potential reversible mechanism of resistance with administration of hypomethylating agents. We evaluated the safety and tolerability of guadecitabine and irinotecan in patients with mCRC previously treated with irinotecan. PATIENTS AND METHODS In this 3+3 dose-escalation study, patients with mCRC previously exposed to irinotecan received guadecitabine days 1 to 5 of a 28-day cycle and irinotecan 125 mg/m2 days 8 and 15 [dose level (DL) 1, guadecitabine 45 mg/m2; DL -1: guadecitabine 30 mg/m2; DL -1G: guadecitabine 30 mg/m2 with growth factor support (GFS); DL 1G: guadecitabine 45 mg/m2 with GFS]. RESULTS Twenty-two patients were treated across four DLs. Dose-limiting toxicities were neutropenic fever (DL 1 and -1G), biliary drain infection (DL -1), colonic obstruction (DL -1), and severe dehydration (DL 1G). Most common toxicities were neutropenia (82% any grade, 77% Grade 3/4), neutropenic fever (23%), leukopenia (73% any grade, 50% Grade 3/4), and injection site reactions (64% total, 0% Grade 3/4). Patients received a median of 4.5 cycles of treatment; 12/17 evaluable patients had stable disease as best response, with one having initial disease progression but subsequently durable partial response. Circulating tumor DNA showed decrease in global demethylation by LINE-1 after treatment. CONCLUSIONS We report the first study of chemo-priming with epigenetic therapy in gastrointestinal cancers. Guadecitabine 45 mg/m2 and irinotecan 125 mg/m2 with GFS was safe and tolerable in patients with mCRC, with early indication of benefit. These data have provided the basis for an ongoing phase II randomized, multicenter trial.
Collapse
Affiliation(s)
- Valerie Lee
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Judy Wang
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Marianna Zahurak
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Elske Gootjes
- Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | - Henk M Verheul
- Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | - Rose Parkinson
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Zachary Kerner
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Anup Sharma
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Gary Rosner
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Daniel Laheru
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Dung T Le
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Ellen Lilly
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Thomas Brown
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Stephen Baylin
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Nita Ahuja
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Nilofer Azad
- Johns Hopkins University School of Medicine, Baltimore, Maryland.
| |
Collapse
|
4
|
Lee V, Wang J, El Khoueiry A, Verheul H, Gootjes E, Sharma A, Kerner Z, Jones P, Baylin S, Lilly E, Ahuja N, Brown T, Azad N. Abstract CT017: A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-ct017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment of IRI-resistant CRC lines with a DNA methyltransferase inhibitor (DNMTi) can induce IRI re-sensitization. We theorized that combination of next generation DNMTi GUA+IRI would overcome resistance in previously IRI-treated mCRC pts.
Methods: mCRC pts with prior IRI exposure were enrolled in a 3+3 Phase I, dose escalation study to define the maximum tolerated dose (MTD) and dose limiting toxicities of GUA+IRI. Pharmacodynamics studies were planned on pre- and post-treatment tumor biopsies (C1D8); serial blood was also taken. Pts were enrolled to 4 dose levels (DL) of GUA SQ qd D1-5 with IRI 125mg/m2 D8 and 15: GUA 45mg/m2 (DL 1), 30mg/m2 (DL -1), 30mg/m2 with growth factor support (GFS) (DL -1G), and 45mg/m2 with GFS (DL 1G) of a 28 day cycle.
Results: 22 heavily pre-treated pts were enrolled (DL 1 = 6, DL -1 = 3, DL -1G = 7, DL 1G = 6); the MTD was established at DL 1G. Grade (G) 3-5 toxicities attributed to therapy were hematologic [neutropenia (16), neutropenic fever (5), anemia (3), thrombocytopenia (2)]. Other G3-4 toxicities were diarrhea (3), fatigue (2), and dehydration (2). There was one death on study possibly due to study treatment (febrile neutropenia). There were some dose reductions of IRI (6) or GUA (3). Median cycles of therapy were 4 months (range 1-14). 15 pts had at least one restaging scan, 12:SD and 1:PR. LINE-1 methylation analysis on serial biopsies revealed mixed changes in global methylation on C1D8, but LINE-1 of circulating tumor DNA showed consistent, delayed, dose-dependent demethylation with peak demethylation at C2D15.
Conclusions: GUA+IRI is well tolerated and demonstrates potentially compelling activity in mCRC pts with prior IRI exposure. Further testing of the combination is ongoing in a randomized phase II trial (2:1 randomization to GUA+IRI or TAS-102/Regorafenib - provider choice). Clinical trial information: NCT01896856. Supported by Astex Pharma and VARI SU2C/AACR Epigenetics Dream Team. Toxicity attributable to therapy in ≤ 10% of patientsAny GG1/G2G3/G4/G5N (%)N (%)N (%)HematologicNeutropenia16 (73)0 (0)16 (73)Anemia13 (59)10 (45)3 (14)Thrombocytopenia9 (41)7 (32)2 (9)InfectionNon-neutropenic infection6 (27)6 (27)0 (0)Febrile Neutropenia5 (23)0 (0)5 (23) 1 death DL-1GFever9 (41)8 (36)1 (5)GastrointestinalNausea/Vomiting16 (73)16 (73)0 (0)Abdominal discomfort4 (18)4 (18)0 (0)Diarrhea11 (50)8 (36)3 (14)Constipation4 (18)4 (18)0 (0)Increased AST4 (18)3 (14)1 (5)Increased alkaline phosphatase9 (41)8 (36)1 (5)Injection Site Reactions15 (68)15 (68)0 (0)GeneralFatigue10 (45)8 (36)2 (9)Anorexia/Weight loss9 (41)8 (36)1 (5)Alopecia7 (32)7 (32)0 (0)Lower extremity edema5 (23)5 (23)0 (0)Dehydration5 (23)3 (14)2 (9)Headache3 (14)3 (14)0 (0)Taste changes4 (18)4 (18)0 (0)
Citation Format: Valerie Lee, Judy Wang, Anthony El Khoueiry, Henk Verheul, Elske Gootjes, Anup Sharma, Zachary Kerner, Peter Jones, Stephen Baylin, Ellen Lilly, Nita Ahuja, Thomas Brown, Nilofer Azad. A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT017.
Collapse
Affiliation(s)
| | - Judy Wang
- 1Johns Hopkins University, Baltimore, MD
| | | | | | | | | | | | | | | | | | - Nita Ahuja
- 1Johns Hopkins University, Baltimore, MD
| | | | | |
Collapse
|